Human Menopausal Gonadotropin 75 IU vial dosage

What Human Menopausal Gonadotropin is

Class:

Glycoprotein hormone combination purified from human urine (FSH and LH activity)

Also called:

hMG, Menotropins, Menopur

Used for:

FDA-approved prescription injection (Menopur) for development of multiple follicles and pregnancy in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle. Not approved for any indication in men.

Human evidence:

Strong human evidence. FDA has approved menotropins for injection (Menopur) for follicle development in ART cycles, based on the data reviewed for approval, with the dosing schedule on the current label built on a trial of 373 women. Separately, published human studies have tested hMG combined with hCG to restore spermatogenesis in men with hypogonadotropic hypogonadism - including a 2019 study of 220 men that the abstract describes as dividing patients between treatments rather than randomising them - real clinical evidence for that off-label male use, though not in a population defined specifically by testosterone-therapy-induced suppression.

Half-life:

FSH activity: 11-13 hours in the multiple-dose phase, per the label. No half-life is stated for LH activity.

US status:

FDA-approved · prescription only. Approved as a prescription injection (Menopur) for follicle development in ART cycles in women; requires a prescriber and a fertility-monitoring protocol (ultrasound and/or serum estradiol). No FDA-approved indication exists for men - off-label use for male fertility support is a prescriber's clinical decision, not a labeled use, and no dose for that use has gone through FDA review.

The full picture, with every study: Human Menopausal Gonadotropin guide.

How to mix a 75 IU Human Menopausal Gonadotropin vial

For this vial: 3 mL of bacteriostatic water makes 25 IU/mL, so 450 IU is 18 mL (more than one 1 mL syringe holds). Pick a different volume from the units table if you want bigger or smaller draws; the number of doses stays the same.

1. Wipe the rubber stoppers of both the peptide vial and the bacteriostatic water vial with an alcohol swab and let the alcohol dry. ^[2][3]
2. With a new sterile needle and syringe, draw up the amount of bacteriostatic water you have chosen for the dilution. ^[2][3][4]
3. Inject the water into the peptide vial by aiming the stream against the inside glass wall, which helps prevent foaming. ^[5]
4. Swirl or roll the vial gently until the powder has fully dissolved; do not shake it. Do not inject the solution if it is cloudy or has particles in it. ^[2][3][5]
5. Label the vial with the date and time it was mixed, the amount of water added and how long it can be used after mixing. ^[2]
6. Store the mixed vial in the refrigerator at 2-8°C (36-46°F) and do not freeze it. ^[5]

Step by step with pictures: how to reconstitute peptides. About the water itself: bacteriostatic water.

Storing Human Menopausal Gonadotropin vials

• Freeze-dried (lyophilized) peptide keeps far longer than peptide in solution; peptide suppliers advise storing the powder at -20°C away from bright light. ^[6]
• Protect peptide vials from heat and light. ^[6][7]
• Avoid repeated freeze-thaw cycles; a prescription peptide label also says not to freeze a vial once it has been mixed. ^[5][6]
• Once a multi-dose vial, such as bacteriostatic water, has been opened (needle-punctured), date it and discard it within 28 days unless its manufacturer states another date. ^[8][9]

More detail: peptide storage and shelf life.

Injecting safely

• Clean the injection site with an alcohol swab and let the skin dry completely before injecting. ^[10][11]
• Pinch up a fold of skin and fat (not muscle) and insert the needle at a 45- to 90-degree angle: 90 degrees where there is enough fatty tissue, 45 degrees where there is little. ^[10][11][12]
• Pulling back on the plunger (aspiration) is not necessary for a subcutaneous injection, because the chance of the needle being in a blood vessel is small. ^[10]
• Inject slowly, at roughly 10 seconds per mL. ^[10]
• Common sites are the belly, the thigh and the upper arm; rotate sites, keeping each injection at least 1 inch (2.5 cm) from the last. ^[5][10][11]

Hygiene and warning signs

• Use a new sterile needle and syringe for every injection and every time you enter a vial; never reuse them. ^[4][8][11]
• Never share needles, syringes or pens with anyone, even if the needle is changed; unsafe injection practices spread hepatitis B, hepatitis C and HIV. ^[4][7][8]
• Put used needles and syringes in a sharps disposal container straight away (FDA-cleared if possible), never loose in the trash, recycling or toilet, and dispose of the container following your community's guidelines. ^[13][14]
• Contact a health care provider if the injection site shows signs of infection, such as redness, swelling, red streaks or a fever. ^[11]

Where to inject: subcutaneous injection sites.

How Human Menopausal Gonadotropin works

• Menotropins (hMG) is a mix of gonadotropins extracted and purified from the urine of postmenopausal women. Each Menopur vial carries 75 IU of follicle-stimulating hormone (FSH) activity and 75 IU of luteinising hormone (LH) activity, and hCG is also detectable in the product. ^[1]
• Given for 7 to 20 days, it makes ovarian follicles grow and mature in women who do not have primary ovarian failure. It usually does not cause ovulation by itself: a separate hCG dose is needed once the follicles are mature. ^[1]
• The label reports an elimination half-life for its FSH activity of 11 to 13 hours with repeated dosing, similar whether it was injected under the skin or into muscle. ^[1]

What the Human Menopausal Gonadotropin research found

Human evidence: strong human evidence. Each result says what was studied.

• FDA labelIn the trial behind approval, 373 women having IVF or ICSI were randomised to Menopur. 23% had a continuing pregnancy at 10 weeks or more, which met the trial's test for being no worse than recombinant FSH, and 26% had a clinical pregnancy. ^[1]
• Human studyA 2026 Cochrane review of 59 randomised trials (18,119 women having IVF or ICSI) found live birth was probably lower with recombinant FSH than with hMG or highly purified hMG (odds ratio 0.83; 15 studies, 4,793 women). OHSS was probably higher with recombinant FSH (odds ratio 1.42; 37 studies, 9,813 women). The evidence was moderate certainty. ^[15]
• Human studyIn a 2019 study of 220 men with hypogonadotropic hypogonadism, combined hCG and hMG injections produced sperm in 26 men and pulsatile GnRH infusion in 62, reported as 25% against 53%, though the paper's group sizes do not match these percentages. Sperm first appeared after an average of 10.9 months with hCG/hMG against 6.2 months with GnRH. ^[16]
• Human studyIn a 2019 non-randomised study of 28 azoospermic men with congenital hypogonadotropic hypogonadism, 83.3% of the 18 given cyclical hCG/hMG reached spermatogenesis within 24 months, against 90% of the 10 on a gonadorelin pump. That difference was not significant, but the pump group got there sooner (median 6 against 14 months). ^[17]

Human Menopausal Gonadotropin side effects and risks

The label's safety data come only from women in fertility treatment; there is no FDA-reviewed safety record for use in men.

• FDA labelIn two trials of 434 women having IVF or ICSI, the reactions seen in 2% or more were abdominal pain (6.7%), headache (6.2%), OHSS (6.2%), injection-site pain or reaction (3.9%), abdominal cramps (3.0%), abdominal enlargement (2.3%) and injection-site inflammation (2.3%). ^[1]
• FDA labelOHSS occurred in 7.2% of the 373 women treated in the IVF trial. It is a sharp rise in vascular permeability that can move fluid quickly into the abdomen, chest and sometimes around the heart. It peaks about 7 to 10 days after treatment and is worse if pregnancy occurs. ^[1]
• FDA labelMultiple pregnancy was seen on ultrasound in 35.3% of pregnancies (30 of 85) in the IVF trial. ^[1]
• FDA labelSerious lung conditions and blood clots have been reported with gonadotropin treatment, with or without OHSS. These include pulmonary embolism, stroke and arterial occlusion, and in rare cases they have been fatal. Ovarian torsion has also been reported. ^[1]
• FDA labelThe label says miscarriage risk is increased with gonadotropin products, though causality has not been established. Menopur is contraindicated in pregnancy because it may cause fetal harm. ^[1]
• Human studyIn a 2019 study of men given cyclical hCG/hMG for congenital hypogonadotropic hypogonadism, there was a tendency towards high testosterone levels, associated with more facial acne and breast tenderness. ^[17]

Other things to know

• Ovarian hyperstimulation syndrome (OHSS): a dramatic increase in vascular permeability that can progress rapidly; occurred in 7.2% of 373 women in the IVF trial on the label and can involve fluid in the abdomen, chest or, rarely, around the heart.
• Multiple pregnancy: in the same trial, multiple pregnancy on ultrasound occurred in 35.3% of pregnancies (30 of 85); the label also notes ectopic pregnancy may be more common because infertile women having ART often have tubal abnormalities, and that miscarriage risk is increased with gonadotropin products, though causality has not been established.
• Pulmonary and vascular events - including venous thromboembolism, pulmonary embolism, stroke and arterial occlusion - have been reported, both with and separate from OHSS, rarely fatal, with higher risk in women with a personal or family history of thrombosis.
• Pregnancy Category X: contraindicated in pregnancy because it may cause fetal harm; also contraindicated in primary ovarian failure, uncontrolled thyroid/adrenal/pituitary disorders, hormone-dependent tumors, and undiagnosed abnormal uterine bleeding.
• No FDA-approved use, dosing, or safety record exists for men. The clinical-trial evidence for off-label male use is in hypogonadotropic hypogonadism, not testosterone-therapy-induced hypogonadism specifically, and reported success rates vary widely between studies.

Reported side effects and what the studies measured: Human Menopausal Gonadotropin side effects.

Where this vial size comes from

Human Menopausal Gonadotropin is sold as a 75 IU vial by the pages below, each checked on the date shown. I list them as evidence that this size exists, not as a recommendation to buy from them.

• DailyMed (NIH/FDA) — Menopur labellabelLists it as: "containing 75 IU FSH and 75 IU of LH activity" per vial · checked 2026-09-28
• SwissChemsvendorLists it as: "HMG 75 IU" — Total Compound Content: 75 IU per vial · checked 2026-09-28

The doses come from the FDA label on the Human Menopausal Gonadotropin dosing page, and every number on this page is arithmetic on those doses and this vial size.

Questions

How much water do I add to a 75 IU Human Menopausal Gonadotropin vial?

There is no single correct amount: water changes how many units a dose is, not how many doses the vial holds. With 3 mL the vial is 25 IU/mL and 450 IU is 18 mL (more than one 1 mL syringe holds). The units table gives 1, 2, 3 mL.

How many doses are in a 75 IU Human Menopausal Gonadotropin vial?

.

What does 1 unit equal in a 75 IU Human Menopausal Gonadotropin vial?

0.75 IU with 1 mL, 0.38 IU with 2 mL, 0.25 IU with 3 mL of bacteriostatic water, on a U-100 syringe.